This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Certain human immunodeficiency virus (HIV)–infected patients, within 6 to 18 months of the initiation of antiretroviral therapy, develop fat redistribution abnormalities consisting of body peripheral fat wasting with central fat deposition.^1-2 Treatment of these morphological abnormalities remains a difficult challenge for case management. However, there are few clinical data to support the ability of amprenavir (Agenerase) to cause less lipodystrophy. We describe a patient whose buffalo hump was reduced by changing his regimen from indinavir sulfate (Crixivan) to amprenavir.

Report of a Case

A 52-year-old man with no medical history of opportunistic infections or cancer was diagnosed as having HIV infection in October 1991. He was initially treated with zidovudine (Retrovir) in 1992. Zalcitabine (Hivid) was added to his regimen, which was changed to didanosine (Videx) in 1994. In April 1996, therapy with stavudine (Zerit), 40 mg twice daily, lamivudine (Epivir), 150 mg twice daily, and indinavir sulfate, 800 mg three times a day, . . . [Full Text of this Article]

Comment


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?